RxDoctor Payments Data

Louis Alpern

El Paso, TXNPI 1295798304

Payments from drug & device makers

What this record shows

This record is dominated by other: $19,586 of the $20,472 with a category attached, or 95.7%. Carl Zeiss Meditec, Inc. accounts for 95.7% of it on its own, with 5 other manufacturers making up the rest. 2022 is the largest year on record at $19,586, more than ten times the $826 reported in 2019.

$20,472in general payments, 2019–2025

Across 16 payments — averaging $1279.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$20K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$292
  • Novartis$264
  • Shire North American Group Inc$136
  • Alcon$134
  • Biotissue Holdings Inc.$60
$1,036,707in research payments, 2019–2025

Across 130 payments — averaging $7974.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$609K
  • Bausch Health US, LLC$158K
  • Kala Pharmaceuticals, Inc.$129K
  • Ocular Therapeutix, Inc.$86K
  • Aerie Pharmaceuticals, Inc.$36K
  • Alcon Research LLC$19K

What the payments were for

  • Food & beverage$8864%
  • Other$19,58696%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →